JERUSALEM, April 10 /CNW/ -- Oramed Pharmaceuticals, Inc (OTC Bulletin
Board: ORMP, FTSE: OJU) is proud to announce the addition of Dr. Harold Jacob
to its advisory board.
Dr. Harold Jacob has a strong background, both in medical sciences as
well as biotechnology and medical devices. He practiced clinical
gastroenterology in New York and served as Chief of Gastroenterology at St.
Johns Episcopal Hospital and South Nassau Communities Hospital, and was a
Clinical Assistant Professor of Medicine at SUNY. Dr. Jacob founded and
served as Editor in Chief of Endoscopy Review and has authored numerous
publications in the field of gastroenterology.
Dr. Jacob is president of Medical Instrument Development Inc., which is a
company which provides a range of support and consulting services to start-up
and early stage companies as well as patenting it's own proprietary medical
devices and biologicals. He has advised a spectrum of companies including
Med-Dynamix Ltd., Ballard Medical, The BioBalance Corporation, as well as
others. He served as a consultant and then as the Director of Medical Affairs
at Given Imaging Ltd., which is the company that developed the first
swallowable wireless pill camera for inspection of the intestine. He has
licensed patents to a number of companies including Kimberly Clark Ballard.
Dr. Jacob is presently CEO of NanoVibronix, a medical device company using
surface acoustics to prevent catheter acquired infection as well as other
CEO Nadav Kidron states, "We are honored to have Dr. Harold Jacob advise
us, and look forward to working with him to complete development of the our
oral insulin, which will simplify the lives of millions of diabetics and
realize the immense growth potential that Oramed holds."
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals' is an Israeli based company focused on the
development of oral delivery solutions based on proprietary technology.
Diabetes is one of the most rapidly growing diseases in the world and is one
that requires constant and often unpleasant monitoring and drug therapy
regimen. Oramed is currently developing an orally soft gel insulin capsule for
the treatment of diabetes. The Company is also pursuing the development of
oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website:
Investor Relations Contact:
Oramed Pharmaceuticals, Inc.
For further information:
For further information: Vinisha Agnihotri, Oramed Pharmaceuticals,
Inc., +1-646-467-2252, or email@example.com Web Site: